| 1 |
31383939 | HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis. | 2020 Feb |
7 |
| 2 |
28786423 | Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. | 2018 May 22 |
11 |
| 3 |
28253087 | Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. | 2017 Mar |
3 |
| 4 |
25987243 | Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. | 2016 Apr |
2 |
| 5 |
27989141 | No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury. | 2016 Dec 19 |
2 |
| 6 |
26098642 | The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. | 2015 |
5 |
| 7 |
26265235 | Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms. | 2015 |
2 |
| 8 |
24687830 | Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. | 2014 Aug 1 |
5 |
| 9 |
22357454 | Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. | 2012 Apr |
1 |